Oncology Research Program Overview
The oncology research program at Parkview is uniquely situated in a multi-disciplinary and inter-collaborative environment that fosters strong communication among physician investigators and their teams from several disciplines including medical oncology, interventional endoscopy, radiation oncology, surgery, and others.
Every patient at the PCI is considered for participation in research trials through presentation at weekly cross-disciplinary tumor board meetings. Patients are presented at tumor board within 3 weeks of diagnosis to allow for early capture of clinical trial eligibility. Disease site specific teams allow for clinical trial focus, subspecialized care, inter-disciplinary collaboration, and operational efficiency. These Tumor Site Teams meet monthly, and ongoing clinical trial progress and status is discussed at each meeting.
The PCI is accredited by the Commission on Cancer, with a research enrollment percentage exceeding 6% annually. The oncology research program is a full voting member of the NRG cooperative group with enrollments in cooperative group trials exceeding 25 patients per year. The research teams receive consistent and positive feedback from study sponsors and collaborators regarding efficient enrollment and execution of clinical trials that require extensive crosstalk among multi-disciplinary teams.
For more information: Parkview Cancer Institute